Orphan drug status approval for Acanthamoeba Keratitis received by Profounda for Miltefosine

PR Newswire
Dec 31, 2016
1 min read

Orphan indication received by Profounda is for the treatment of Acanthamoeba Keratitis, also commonly known as AK usually associated with contact lens wear.

ORLANDO, Fla.

Comments

Patient survives Brain Eating Amoeba

Profounda OutLicenses right to development product

Company formation complete

Here we come 2023!

PROFOUNDA, INC.

Profound Insights Lead to Better Products.

Check some of our Products!

Orphan drug status approval for Acanthamoeba Keratitis received by Profounda for Miltefosine

Comments

Featured Posts

Patient survives Brain Eating Amoeba

Profounda OutLicenses right to development product

Company formation complete

Recent Posts

Here we come 2023!

Generic to Arestin Microspheres by Bausch Health (Orapharma) receives Competitive Generic Therapy De

DOG AND HUMANS GET GREAT RESULTS

Sales exceed $2 Million for first year of Profounda's Commercial Presence in the USA

Orphan drug status approval for Acanthamoeba Keratitis received by Profounda for Miltefosine

Profounda Inc. receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencep

CNN report on Survivor of Brain Eating Amoeba

Patient survives Brain Eating Amoeba

Profounda working with local Health Officials in fight to save patients life.

Profounda Licensed in Florida

Archive

Search By Tags

Follow Us